Instructions Reodar infusion solution 200 ml
Composition
active ingredients: 1 ml of solution contains sorbitol 60.0 mg, sodium (S)-lactate solution (calculated as 100% substance) 19.0 mg, sodium chloride 6.0 mg, calcium chloride dihydrate (calculated as calcium chloride) 0.1 mg, potassium chloride 0.3 mg, magnesium chloride hexahydrate (calculated as magnesium chloride) 0.2 mg;
excipient: water for injections.
Dosage form
Solution for infusion.
Main physicochemical properties: clear colorless liquid.
Theoretical osmolarity: 891 mOsmol/L; pH 6.0-7.6;
Ionic composition: 1 liter of the drug contains Na+ – 272.20 mmol, K+ – 4.02 mmol, Ca++ – 0.90 mmol, Mg++ – 2.10 mmol, Cl- – 112.69 mmol, Lac- – 169.55 mmol.
Pharmacotherapeutic group
Solutions that affect electrolyte balance. Electrolytes in combination with other drugs. ATX code B05B B04.
Pharmacological properties
Pharmacodynamics.
The drug Reodar® has a rheological, anti-shock, detoxification and alkalizing effect and stimulates intestinal peristalsis. The main pharmacologically active substances of the drug are sorbitol and sodium lactate. In the liver, sorbitol is first converted into fructose, which is then converted into glucose, and then into glycogen. Part of the sorbitol is used for urgent energy needs, the other part is stored as a reserve in the form of glycogen. Isotonic sorbitol solution has a disaggregant effect and thus improves microcirculation and tissue perfusion.
Unlike bicarbonate solution, correction of metabolic acidosis with sodium lactate proceeds more slowly as it is incorporated into the metabolism, and there are no sharp fluctuations in pH. The effect of sodium lactate is manifested 20-30 minutes after administration.
Sodium chloride has a rehydrating effect, replenishing the deficiency of sodium and chlorine ions in various pathological conditions.
Calcium chloride replenishes the deficiency of calcium ions. Calcium ions are necessary for the transmission of nerve impulses, contraction of skeletal and smooth muscles, myocardial activity, bone formation, blood clotting. Reduces the permeability of cells and vascular walls, prevents the development of inflammatory reactions, increases the body's resistance to infections.
Potassium chloride restores water and electrolyte balance. Has a negative chrono- and bathmotropic effect, in high doses - a negative ino-, dromotropic and moderate diuretic effect. Participates in the process of conducting nerve impulses. Increases the content of acetylcholine and causes excitation of the sympathetic division of the autonomic nervous system. Improves skeletal muscle contraction in muscular dystrophy, myasthenia.
Magnesium is the second most common cation in intracellular fluid. Magnesium chloride is a necessary cation for metabolism, participates in energy-intensive enzymatic processes, the construction of protein molecules, oxidative phosphorylation, muscle contraction and transmission of nerve impulses, exhibits an antispastic effect, and promotes the excretion of cholesterol from the body.
Pharmacokinetics.
Sorbitol is quickly included in the general metabolism, 80-90% of it is utilized in the liver and accumulates in the form of glycogen, 5% is deposited in the tissues of the brain, heart muscle and skeletal muscles, 6-12% is excreted in the urine. When introduced into the vascular bed, sodium, CO2 and H2O are released from sodium lactate, which form sodium bicarbonate, which causes an increase in the alkaline reserve of the blood.
The distribution and excretion of sodium (Na+) and chlorine (Cl-) are largely controlled by the kidneys, which maintain a balance between intake and excretion.
Sodium chloride is rapidly excreted from the vascular bed, only temporarily increasing the volume of circulating blood. It increases diuresis.
The concentration of calcium in the blood plasma is regulated by parathyroid hormone, calcitonin, and vitamin D. About 47% of the calcium in the plasma is in the ionized, physiologically active form, about 6% is complexed with anions such as phosphate or citrate, and the rest is bound to proteins, mainly albumin. If the concentration of albumin in the blood plasma increases (as in dehydration) or decreases (as is often the case in malignant neoplasms), this affects the proportion of ionized calcium. Thus, the total concentration of calcium in the blood plasma is usually regulated by the content of albumin in the plasma. Excess calcium is mainly excreted by the kidneys. Unabsorbed calcium is excreted in the feces, in particular with bile and pancreatic secretions. A small amount is excreted in sweat, as well as in the skin, hair, and nails. Calcium crosses the placenta and is excreted in breast milk.
Factors that affect the transfer of potassium between intracellular and extracellular fluids, such as acid-base disturbances, can alter the relationship between plasma concentrations and total body stores. Normally, potassium is excreted by the kidneys in the urine (it is secreted in the distal tubules in exchange for sodium or hydrogen ions); the remainder is excreted in the feces and, to a small extent, in sweat. The kidneys have a poor capacity to retain potassium, and a small amount of potassium is excreted in the urine even when the body is severely depleted.
Indication
- To improve capillary blood flow for the purpose of prevention and treatment of traumatic, surgical, hemolytic, toxic and burn shock, acute blood loss, burn disease;
- for infectious diseases accompanied by intoxication, in particular as part of the complex treatment of patients with community-acquired pneumonia, purulent peritonitis, exacerbation of chronic hepatitis; for sepsis;
- for preoperative preparation and in the postoperative period;
- to improve arterial and venous blood circulation in order to prevent thrombosis, thrombophlebitis, endarteritis, and Raynaud's disease.
Contraindication
Individual hypersensitivity to the components of the drug. Reodar® should not be used in alkalosis, as well as in cases where the infusion of large volumes of fluid is contraindicated (cerebral hemorrhage, thromboembolism, cardiovascular decompensation, grade III arterial hypertension, decompensated heart disease, terminal renal failure), dehydration, oliguria.
Interaction with other medicinal products and other types of interactions
Do not use as a solvent carrier for other medicinal products.
Application features
When using the drug, it is necessary to monitor the indicators of acid-base status and blood electrolytes, liver function and blood pressure. Administer with caution to patients with calculous cholecystitis.
Important information about excipients.
The medicine contains sorbitol, therefore it should not be used in patients with rare hereditary fructose intolerance.
Use during pregnancy or breastfeeding
There is no data on contraindications during pregnancy or breastfeeding.
Ability to influence reaction speed when driving vehicles or other mechanisms
Since the drug is used in a hospital setting, there is no data on such effects.
Method of administration and doses
Reodar® is administered intravenously to adults by drip at a rate of 40-60 drops per minute. If necessary, jet injection of the drug is allowed after conducting a test by drip injection at a rate of 30 drops/min. After the injection of 15 drops, the use of the drug should be stopped, and after 3 minutes, in the absence of a reaction, Reodar® is administered by jet injection.
In case of traumatic, burn, postoperative and hemolytic shocks, adults should be administered 600-1000 ml (10-15 ml/kg of the patient's body weight) once and repeatedly 600-1000 ml (10-15 ml/kg of the patient's body weight), first by jet, then by drip.
For purulent peritonitis, adults should be administered 400–1200 ml intravenously by drip.
For community-acquired pneumonia and exacerbation of chronic hepatitis, adults should be administered 400 ml (6-7 ml/kg of body weight) intravenously.
In acute blood loss, adults should be administered 1500-1800 ml (up to 25 ml/kg body weight). In this case, Reodar® infusions are recommended to be performed at the pre-hospital stage in a specialized ambulance.
In the preoperative period and after various surgical interventions - at a dose of 400 ml (6-7 ml/kg of body weight) drip for 3-5 days.
For thrombo-obliterating diseases of blood vessels - at the rate of 8-10 ml/kg of body weight drip, repeated every other day, up to 10 infusions per course of treatment.
Method of application
Do not insert the needle(s) into any places on the polymer vial that are not intended for this purpose, but only into sterile ports!
To carry out infusion treatment, you must follow the following algorithm:
- Remove the protective plastic cover with first-time opening control (if present).
- Tear off the safety valve(s) No. 1 as shown in Fig. 1 and Fig. 2 (the manufacturer may use different types and materials for the safety valves).
- Remove the cap from the needle and insert it into any of the special ports No. 2 of the infusion drug vial (see Fig. 1 and Fig. 2).
- Another sterile port can be used to introduce other drugs into the infusion bottle (No. 4, see Fig. 3), or, in case of insufficient flow rate, for the air needle (No. 4, see Fig. 3).
- Hang the solution bottle using the special ring No. 3 located at the bottom of the bottle (see Fig. 3).
Children.
There is insufficient data on experience with use in children.
Overdose
There are phenomena of alkalosis, which quickly disappear on their own if the drug is immediately stopped, sometimes collapse, dehydration (due to increased diuresis). If the rate of administration is exceeded, tachycardia, increased blood pressure, shortness of breath, headache, chest pain, abdominal pain may develop. These symptoms quickly disappear after stopping or significantly reducing the rate of solution administration.
Side effects
Gastrointestinal: nausea, vomiting.
From the nervous system: tremor, headache, dizziness, general weakness.
From the cardiovascular system: increase or decrease in blood pressure, tachycardia, shortness of breath, acrocyanosis.
On the part of the immune system: anaphylactoid reactions, angioedema, hyperthermia.
General disorders and administration site conditions: changes at the injection site, including pain and burning.
Reporting of suspected adverse reactions.
Reporting suspected adverse reactions after the marketing authorisation of a medicinal product is an important procedure. This allows for continued monitoring of the benefit/risk balance of the medicinal product in question. Healthcare professionals should report any suspected adverse reactions through the national pharmacovigilance system.
Expiration date
2 years.
Storage conditions
Store at a temperature not exceeding 25 ° C. Do not freeze.
Keep out of reach of children.
Incompatibility
The drug Reodar® cannot be mixed with phosphate- and carbonate-containing solutions.
Packaging
200 ml in a bottle.
Vacation category
According to the recipe.
Producer
PrJSC "Pharmaceutical Company "Darnitsa".
Location of the manufacturer and address of its place of business.
Ukraine, 02093, Kyiv, Boryspilska St., 13.
